Clinical Trial Detail

NCT ID NCT03325127
Title Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
Recruitment Withdrawn
Gender male
Phase Phase I
Variant Requirements No
Sponsors Bayer
Indications

prostate cancer

Therapies

Abiraterone + Enzalutamide + Radium Ra 223 dichloride

Age Groups: adult senior

No variant requirements are available.